Disease biology drives critical pipeline decisions
Link fragmented biological evidence to build a transparent rationale to de-risk the next decision.
Relevant evidence is not systematically evaluated
In the age of generative AI, the growing challenge is to identify, link and assess relevant biological evidence together.
Most decisions rely on partial evidence
Teams often rely on only 5–20% of available molecular data, while other relevant findings go unnoticed or are difficult to interpret.
Interpretation remains manual and unstructured
Assembling relevant molecular context is an iterative, often undocumented process that can take six months or more, if started at all.
Public and proprietary evidence in one data foundation
Consolidate relevant public studies and your proprietary findings into a modular data foundation tailored to your question. Each dataset keeps its source and definitions, so you can can review the source of each result at any time.
Extend the foundation as your program transitions from discovery to the clinic without having to rebuild it from scratch for each new question.
Cellmap links evidence across omics layers
At the core of the knowing01 platform is our proprietary Cellmap knowledge graph, which maps identifiers, ontologies and synonyms. It links genes, proteins, variants and pathways across datasets, omics layers and organisms such as human, mouse and rat, while preserving the source of each individual finding.
A single search thus delivers releveant evidence, even when studies use different identifiers or biological representations.
A no-code platform for disease and biology experts
Search, compare, filter and export evidence on the knowing01 platform using reproducible workflows, with every result traceable back to its original source.
Use the platform independently or work with our scientific team to turn findings into a transparent rationale for managers and decision-makers.
A structured method for evaluating evidence
The Evidence Convergence Protocol guides your team from defining the question and criteria all the way to documenting what is supported by the evidence. Supporting, contradictory and missing evidence remains visible, ensuring that assumptions are reviewed before the next decision is made.
Apply it on the platform or in collaboration with our Analytics Services team to ensure that your rationale remains consistent across projects.
What our clients say
As a CEO, I’m constantly asked the same question: how will your preclinical data translate into real-world patient outcomes? Until now, we could only speculate based on informed assumptions. With knowing01’s in silico approach, we were able to use existing multimodal data to get a realistic estimate of the proportion of patients we can expect to effectively treat. Within weeks, we had a defensible picture showing our lead program could reach about two thirds of liver cancer patients and that completely changed how we speak to stakeholders.
Dr. Jennifer Altomonte Chief Executive Officer at Fusix BiotechWith the knowing01 expert team, we were able to systematically explore far more public omics data than we had previously considered, using clear and transparent criteria throughout the process. What we appreciated most was that they did not just run analyses and send raw outputs, but actively guided us through the results, brought clarity, supported interpretation, and helped us derive actionable conclusions we could directly use in stakeholder communication.
Dr. Richard Klar Chief Research Officer at SecarnaSelecting the right markers used to be one of the least reproducible parts of our workflow. knowing01 designed a structured, multi-evidence approach that brought clarity and consistency to how we prioritize markers. The result is simple: greater confidence in our decisions and far better reproducibility across projects.
Dr. Sven Wichert Chief Executive Officer at Systasy Bioscience GmbHAccess to this scale of unbiased Multiomics data was a game changer for us. For the first time, we could systematically explore biology across more than 30 I&I indications, something simply out of reach with traditional approaches. This gave us an entirely new level of confidence in where and how to focus our efforts. Along the way, we uncovered patterns that reshaped how we think about the underlying biological processes.
Dr. Enrico Girardi Chief Scientific Officer at Solgate GmbHWe partnered with knowing01 to build a comprehensive 360° perspective in a novel target organ with a broad coverage of omics evidence, integrating 13 public studies across 96 human, tissue-level Multiomics datasets with cell type-specific expression across two indications and tissue baseline information. Within weeks, we reached an in depth of understanding of our target linked to a specific organ. knowing01 translated this into clear, actionable insights, enabling us to engage key stakeholders with confidence.
Head of Research at Biotech in Drug DiscoveryWorking with knowing01 helped us break down a complex question into clear, manageable parts. Their structured approach gave us a systematic way to work with large volumes of omics data. The resulting insights are now informing our next program decision.
Dr. Markus Krohn Chief Scientific Officer at Caladrix
From our client projects
12+ client R&D programs
Applied in discovery and translational programs for biotech and pharma clients.
From 500 to 5,000+ patients
After relevant public datasets were added to the evidence in a target validation project.
Data foundation in ~1 week
300+ datasets collected, prepared and harmonized for one client question.
Figures come from our client projects and depend on the question and data scope.
See how the Data Center works.
Questions about knowing01
What does knowing01 do?
knowing01 is a TechBio software and services company in Biological Evidence Intelligence. We help biotech and pharma scientists contextualize biological evidence across studies, omics layers and biological settings, so they can build a transparent, evolving program rationale for development decisions.
What is Biological Evidence Intelligence?
Biological Evidence Intelligence means connecting and evaluating biological findings across studies and evidence types to support an evolving program rationale. It shows what the evidence supports, where it conflicts and what remains unresolved, while your team keeps responsibility for the decision.
Which decisions does knowing01 support?
Development decisions from discovery through translation and early clinical development. Examples include putting disease markers into context, prioritizing markers for experimental follow-up, testing a target hypothesis and comparing candidate indications. See our use cases.
Do we use the platform ourselves or work with your team?
Both are possible. Scientists can use the knowing01 platform independently within supported workflows, or work with our Analytics Services team around the same evidence foundation.
How long does it take?
With the knowing01 platform, a decision workflow typically takes 2 to 4 weeks, including the initial data foundation. With our Analytics Services, a Focus View answers one core question in about 4 weeks, and larger engagements take about 6 to 12 weeks depending on scope.
What does knowing01 not do?
knowing01 does not replace experimental validation. We connect and evaluate the evidence and guide your team through the decision it informs, while the final program decision stays with you.